enGene Announces Full Year 2025 Financial Results and Business Developments

December 23, 2025 - 05:52

BOSTON & MONTREAL, December 22, 2025—enGene Holdings Inc., a clinical-stage company specializing in non-viral genetic medicines, has released its financial results for the year ending October 31, 2025. The company has also shared key updates regarding its business operations.

In the report, enGene highlighted its ongoing commitment to advancing its innovative therapies aimed at addressing unmet medical needs. The financial results reflect the company's strategic investments in research and development, which are essential for the progression of its clinical programs.

The leadership team expressed optimism about the future, noting that the advancements made over the past year position the company well for continued growth. They underscored the importance of their proprietary technology in delivering effective genetic treatments.

As enGene moves forward, it remains focused on expanding its pipeline and exploring partnerships that could enhance its capabilities in the genetic medicine landscape. The company is dedicated to making a significant impact on patient outcomes through its pioneering approaches.